Abstract: A venous cannula is disclosed having an insertion hole near the distal end and a leading end hole at the distal end. The cannula further includes a removable sleeve that is fitted within the insertion hole and preferably extends at least from the insertion hole to the leading end hole. In a preferred embodiment, the cannula also includes an introducer that fits within the removable sleeve and extends at least the length of the removable sleeve. The removable sleeve and introducer are designed to facilitate use of the Seldinger technique with the venous cannula. Additionally, a method for use of the Seldinger technique with the cannula is disclosed.

Abstract: A method for non-invasively measuring the oxygen saturation of an in utero fetus's blood using near-infrared spectroscopy. Exemplary methods include placement of a sensor on the outside of the uterus approximate the placenta. Other exemplary methods include inserting a probe into the uterus. Sensors may be positioned approximate a particular portion of the fetus, such as the brain or kidney, to measure the oxygen saturation within the particular portion of the fetus.

Abstract: The present invention relates to a method for assessing the likelihood of the presence or formation of fetal heart disease (such as HLHS) in a fetus. In this methodology, the mother, either before or during pregnancy, is tested for the presence of anti-strep antibodies. If positive, the fetus is evaluated and monitored for the presence of fetal heart disease; the fetus can be treated, if appropriate. In addition, either prior to pregnancy or during the first trimester, the mother can be treated to prevent the formation of such antibodies or to neutralize their presence or effect fetal heart tissue.

Abstract: The present invention relates to a method for assessing the likelihood of the presence or formation of fetal heart disease (such as HLHS) in a fetus. In this methodology, the mother, either before or during pregnancy, is tested for the presence of anti-strep antibodies. If positive, the fetus is evaluated and monitored for the presence of fetal heart disease; the fetus can be treated, if appropriate. In addition, either prior to pregnancy or during the first trimester, the mother can be treated to prevent the formation of such antibodies or to neutralize their presence or effect fetal heart tissue.

Abstract: A venous cannula is disclosed having an insertion hole near the distal end and a leading end hole at the distal end. The cannula further includes a removable sleeve that is fitted within the insertion hole and preferably extends at least from the insertion hole to the leading end hole. In a preferred embodiment, the cannula also includes an introducer that fits within the removable sleeve and extends at least the length of the removable sleeve. The removable sleeve and introducer are designed to facilitate use of the Seldinger technique with the venous cannula. Additionally, a method for use of the Seldinger technique with the cannula is disclosed.

Abstract: The present invention relates to a method for assessing the likelihood of the presence or formation of fetal heart disease (such as HLHS) in a fetus. In this methodology, the mother, either before or during pregnancy, is tested for the presence of anti-strep antibodies. If positive, the fetus is evaluated and monitored for the presence of fetal heart disease; the fetus can be treated, if appropriate. In addition, either prior to pregnancy or during the first trimester, the mother can be treated to prevent the formation of such antibodies or to neutralize their presence or effect fetal heart tissue.